Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial

BACKGROUND: Cabergoline is a long-acting agonist of dopamine, which has a high affinity to dopamine receptors (type 2). Treatment using a dopaminergic agonist reduces hypothalamic stimulation that increases during liver gluconeogenesis, lipids synthesis, and insulin resistance. Our aim was to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahar, Adele, Kashi, Zahra, Daneshpour, Ezzatossadat, Akha, Ozra, Ala, Shahram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059036/
https://www.ncbi.nlm.nih.gov/pubmed/27749534
http://dx.doi.org/10.1097/MD.0000000000004818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059036/
https://www.ncbi.nlm.nih.gov/pubmed/27749534
http://dx.doi.org/10.1097/MD.0000000000004818

Ejemplares similares